TY - JOUR
T1 - Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension
AU - El-Kersh, Karim
AU - Zhao, Carol
AU - Elliott, Gregory
AU - Farber, Harrison W.
AU - Gomberg-Maitland, Mardi
AU - Selej, Mona
AU - Garcia-Ferrer, Josephine
AU - Benza, Raymond
N1 - Funding Information:
This study was funded by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Medical writing support was provided by Laura Evans and Ify Sargeant of Twist Medical and was funded by Actelion Pharmaceuticals US, Inc. (a Janssen Pharmaceutical Company of Johnson and Johnson). R. B.’s institution (Ohio State University Medical Center) is supported by the National Heart, Lung, and Blood Institute , National Institutes of Health .
Funding Information:
The authors have reported to CHEST the following: K. E.-K. has received institutional research grants from UT and Actelion, has participated in advisory boards for UT and Actelion and the speaker bureau for UT, and has acted as a consultant for Acceleron. C. Z. was an employee of Actelion Pharmaceuticals US, Inc., at the time of manuscript development and is a current stockholder of Johnson & Johnson. G. E. is an employee of Intermountain Healthcare, Inc., which receives compensation for G. E.’s service on data safety boards for Lung Biotechnology, Gossamer, and Insmed. H. W. F. is a speaker for Bayer; is a scientific advisory board member for Janssen Pharmaceutical Companies of Johnson & Johnson, Acceleron Pharma, Aerovate, Altavant, and United Therapeutics; and has received research support from Janssen Pharmaceutical Companies of Johnson & Johnson and United Therapeutics. M. G.-M. is a consultant on steering committees and data safety monitoring boards for Acceleron/Merck, Actelion/Janssen, and United Therapeutics. M. S. and J. G.-F. are employees and stockholders of Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. R. B.’s institution has received grants from The American Heart Association, Bayer, and United Therapeutics.
Publisher Copyright:
© 2023
PY - 2023/5
Y1 - 2023/5
N2 - Background: Multiparametric risk assessment tools determine mortality risk in patients with pulmonary arterial hypertension (PAH) by combining invasive and noninvasive variables so management strategies can be tailored to individuals. Research Question: Can a risk score based on common echocardiographic parameters risk-stratify patients with PAH? Study Design and Methods: A Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) echocardiographic risk score (REVEAL-ECHO) was derived using retrospective echocardiographic data from 2,400 adult patients with PAH enrolled in the REVEAL registry database. A stepwise Cox regression model identified echocardiographic parameters significantly predictive of survival. Values were assigned to each selected parameter based on survival at 12 months’ follow-up (Kaplan-Meier estimates). The REVEAL-ECHO risk score was the sum of individual values. Patients were categorized as having low, intermediate, or high risk based on Kaplan-Meier-predicted 12-month survival. Results: The risk score included four echocardiographic parameters—right ventricular (RV) chamber enlargement, reduced RV systolic function, tricuspid regurgitation severity, and pericardial effusion—and accounted for PAH etiology. Higher REVEAL-ECHO risk scores signaled lower probability of 12-month survival. Statistically significant separation of mortality risk was observed among the risk strata: intermediate vs low (hazard ratio [HR], 1.43; 95% CI, 1.17-1.75; P = .0004) and high vs low (HR, 2.60; 95% CI, 2.19-3.10; P < .0001). Augmentation of the REVEAL Lite 2 risk calculator with REVEAL-ECHO risk scores achieved separation of REVEAL Lite 2 into four risk groups and identified a subgroup of patients with a low REVEAL Lite 2 risk score who were at higher risk (intermediate-low risk) and a subgroup of patients with an intermediate REVEAL Lite 2 risk score who also were at higher risk (intermediate-high risk). Interpretation: A REVEAL-ECHO risk score, derived using four echocardiographic parameters, may discriminate risk further when used as an adjunct to current risk assessment scores. Further validation is required.
AB - Background: Multiparametric risk assessment tools determine mortality risk in patients with pulmonary arterial hypertension (PAH) by combining invasive and noninvasive variables so management strategies can be tailored to individuals. Research Question: Can a risk score based on common echocardiographic parameters risk-stratify patients with PAH? Study Design and Methods: A Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) echocardiographic risk score (REVEAL-ECHO) was derived using retrospective echocardiographic data from 2,400 adult patients with PAH enrolled in the REVEAL registry database. A stepwise Cox regression model identified echocardiographic parameters significantly predictive of survival. Values were assigned to each selected parameter based on survival at 12 months’ follow-up (Kaplan-Meier estimates). The REVEAL-ECHO risk score was the sum of individual values. Patients were categorized as having low, intermediate, or high risk based on Kaplan-Meier-predicted 12-month survival. Results: The risk score included four echocardiographic parameters—right ventricular (RV) chamber enlargement, reduced RV systolic function, tricuspid regurgitation severity, and pericardial effusion—and accounted for PAH etiology. Higher REVEAL-ECHO risk scores signaled lower probability of 12-month survival. Statistically significant separation of mortality risk was observed among the risk strata: intermediate vs low (hazard ratio [HR], 1.43; 95% CI, 1.17-1.75; P = .0004) and high vs low (HR, 2.60; 95% CI, 2.19-3.10; P < .0001). Augmentation of the REVEAL Lite 2 risk calculator with REVEAL-ECHO risk scores achieved separation of REVEAL Lite 2 into four risk groups and identified a subgroup of patients with a low REVEAL Lite 2 risk score who were at higher risk (intermediate-low risk) and a subgroup of patients with an intermediate REVEAL Lite 2 risk score who also were at higher risk (intermediate-high risk). Interpretation: A REVEAL-ECHO risk score, derived using four echocardiographic parameters, may discriminate risk further when used as an adjunct to current risk assessment scores. Further validation is required.
KW - REVEAL Registry
KW - echocardiographic parameters
KW - mortality
KW - outcomes
KW - pulmonary arterial hypertension
KW - risk score
UR - http://www.scopus.com/inward/record.url?scp=85153584322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153584322&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2022.12.045
DO - 10.1016/j.chest.2022.12.045
M3 - Article
C2 - 36634897
AN - SCOPUS:85153584322
SN - 0012-3692
VL - 163
SP - 1232
EP - 1244
JO - Chest
JF - Chest
IS - 5
ER -